Waiting for bluebird bio to Sing at ASH [The Motley Fool]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: The Motley Fool
The American Society of Hematology meeting will be a big event for the biotech. bluebird bio ( NASDAQ:BLUE ) released third-quarter earnings last week, but it was an initial look at what the biotech plans to present at the American Society of Hematology (ASH) meeting next month that had investors excited. Bluebird results: The raw numbers Metric Q3 2018 Q3 2017 Year-Over-Year Change Revenue $11.5 million $7.7 million 49% Income from operations ($149.8 million) ($77.7 million) N/A Earnings per share ($2.73) ($1.73) N/A Data source: Bluebird. What happened with Bluebird this quarter? Obviously the biotech's revenue isn't particularly important. It mostly comes from manufacturing costs for the CAR T program that are reimbursed by Bluebird's partner Celgene ( NASDAQ:CELG ) . Most importantly on the financial report, the company ended the quarter with $2.0
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC [Yahoo! Finance]Yahoo! Finance
- SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCCBusiness Wire
- Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate [Seeking Alpha]Seeking Alpha
- Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA [Yahoo! Finance]Yahoo! Finance
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,135.00 price target on the stock.MarketBeat
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 3/15/24 - Form 4
- 3/14/24 - Form 144
- 3/5/24 - Form 4
- REGN's page on the SEC website